Literature DB >> 18726703

Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica.

H Solana1, S Scarcella, G Virkel, C Ceriani, J Rodríguez, C Lanusse.   

Abstract

Fascioliasis causes important economic losses in ruminant species all over the world. Its control is largely based on the use of the flukicidal compound triclabendazole (TCBZ). However, its chemically related benzimidazole anthelmintic albendazole (ABZ) is being successfully used to control TCBZ-resistance flukes. This research gains some insights into the comparative molecular behaviour of both anthelmintics within the target fluke. The goals of the current work were: (i) to assess the competitive binding of ABZ and TCBZ to cytosolic proteins of F. hepatica, and (ii) to evaluate the enantioselective biotransformation of ABZ in microsomal fractions obtained from TCBZ-susceptible and TCBZ-resistant strains of the liver fluke. Cytosolic proteins from fluke specimens bound TCBZ with greater affinity (83%) than ABZ (44%) and the fraction of TCBZ bound to cytosolic proteins was not displaced by ABZ. The microsomes from both -susceptible and resistant flukes sulphoxidized ABZ into ABZ sulphoxide (ABZSO). However, this oxidative activity was 49% higher in microsomes from TCBZ-resistant flukes (P < 0.001) with a predominant production of the (+) ABZSO enantiomer. As earlier shown for TCBZ, the results reported here confirm an enhanced ability for ABZ oxidation in TCBZ-resistant flukes. While this enhanced oxidative metabolism of ABZ may cooperate to the resistance phenomenon, other pharmacodynamic-based mechanisms may be involved, which would explain why, although being chemically-related, ABZ remains efficacious against TCBZ resistant flukes under field conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726703     DOI: 10.1007/s11259-008-9166-3

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  27 in total

1.  Triclabendazole-resistant Fasciola hepatica in southwest Wales.

Authors:  I Thomas; G C Coles; K Duffus
Journal:  Vet Rec       Date:  2000-02-12       Impact factor: 2.695

2.  An experimental study on triclabendazole resistance of Fasciola hepatica in sheep.

Authors:  C P Gaasenbeek; L Moll; J B Cornelissen; P Vellema; F H Borgsteede
Journal:  Vet Parasitol       Date:  2001-02       Impact factor: 2.738

3.  In vitro sulfoxidation of albendazole by ovine liver microsomes: assay and frequency of various xenobiotics.

Authors:  P Galtier; M Alvinerie; P Delatour
Journal:  Am J Vet Res       Date:  1986-02       Impact factor: 1.156

4.  Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.

Authors:  L I Alvarez; H D Solana; M L Mottier; G L Virkel; I Fairweather; C E Lanusse
Journal:  Parasitology       Date:  2005-10       Impact factor: 3.234

5.  Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The netherlands.

Authors:  L Moll; C P Gaasenbeek; P Vellema; F H Borgsteede
Journal:  Vet Parasitol       Date:  2000-07-24       Impact factor: 2.738

6.  Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep.

Authors:  G Virkel; A Lifschitz; J Sallovitz; A Pis; C Lanusse
Journal:  J Vet Pharmacol Ther       Date:  2006-06       Impact factor: 1.786

7.  The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.

Authors:  Mark W Robinson; Jill Lawson; Alan Trudgett; Elizabeth M Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2003-12-03       Impact factor: 2.289

8.  Sulphoxidation of albendazole by the FAD-containing and cytochrome P-450 dependent mono-oxygenases from pig liver microsomes.

Authors:  H S el Amri; X Fargetton; P Delatour; A M Batt
Journal:  Xenobiotica       Date:  1987-10       Impact factor: 1.908

9.  Fasciola hepatica expresses multiple alpha- and beta-tubulin isotypes.

Authors:  Louise A Ryan; Elizabeth Hoey; Alan Trudgett; Ian Fairweather; Marc Fuchs; Mark W Robinson; Emma Chambers; David J Timson; Eimear Ryan; Theresa Feltwell; Al Ivens; Geoffrey Bentley; David Johnston
Journal:  Mol Biochem Parasitol       Date:  2008-02-14       Impact factor: 1.759

Review 10.  Understanding triclabendazole resistance.

Authors:  G P Brennan; I Fairweather; A Trudgett; E Hoey; M McConville; M Meaney; M Robinson; N McFerran; L Ryan; C Lanusse; L Mottier; L Alvarez; H Solana; G Virkel; P M Brophy
Journal:  Exp Mol Pathol       Date:  2007-02-15       Impact factor: 3.362

View more
  2 in total

1.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

2.  Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs.

Authors:  Santiago Radio; Santiago Fontenla; Victoria Solana; Anna C Matos Salim; Flávio Marcos Gomes Araújo; Pedro Ortiz; Cristian Hoban; Estefan Miranda; Valeria Gayo; Fabiano Sviatopolk-Mirsky Pais; Hugo Solana; Guilherme Oliveira; Pablo Smircich; José F Tort
Journal:  Parasit Vectors       Date:  2018-01-24       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.